Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114,331,829
-
Total 13F shares
-
108,822,065
-
Share change
-
-3,522,157
-
Total reported value
-
$518,024,328
-
Put/Call ratio
-
484%
-
Price per share
-
$4.76
-
Number of holders
-
180
-
Value change
-
-$20,807,671
-
Number of buys
-
89
-
Number of sells
-
80
Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q2 2023
As of 30 Jun 2023 FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) had 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 108,822,065 shares of stock of the company.
Largest 10 holders included Redmile Group, LLC, BlackRock Inc., VANGUARD GROUP INC, STATE STREET CORP, Bellevue Group AG, D. E. Shaw & Co., Inc., JOHNSON & JOHNSON, JPMORGAN CHASE & CO, FEDERATED HERMES, INC., and JACOBS LEVY EQUITY MANAGEMENT, INC.
This table shows 183 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.